GlassScriptPhysician profile
Swetha Addagatla
NPI 1376925503
$6,631.49
in general payments reported to CMS, 2019-2025
47 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $1,377 · 2021: $1,203 · 2022: $895 · 2023: $741 · 2024: $726 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.24 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,041.97 | 2019-2025 | Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $722.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $596.67 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.02 | 2019-2024 | Jardiance, Ofev |
| Amgen INC. | $369.45 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $297.06 | 2019-2024 | Arexvy, Shingrix |
| Abbvie INC. | $268.92 | 2019-2023 | Ubrelvy |
| Abbott Laboratories | $243.11 | 2021-2023 | Freestyle Libre 3 |
| Optinose US, INC. | $233.92 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.45 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $167.30 | 2020-2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $157.59 | 2019-2022 | |
| Exact Sciences Corporation | $145.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Currax Pharmaceuticals LLC | $134.56 | 2019-2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Pfizer INC. | $128.87 | 2019-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Addagatla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.